T-O: 0.0 (08:59:00)
Last updated: 10:17
EPS | 7.18 sen |
Trailing PE (Sector Median: 15.3) | 16.6 |
PEG | 0.68 |
Altman Z | 1.3 |
Beaver | 0.037 |
Current Ratio | 2.19 |
Debt-Equity (DE) Ratio | 0.89 |
FCF Yield | -0.32 % |
Revenue QoQ | 11.71 % |
Revenue YoY | 14.03 % |
Profit QoQ | 15.2 % |
Profit YoY | 9.09 % |
Profit Margin (Sector Median: 5.4) | 10.38 % |
ROE (ROIC: 7.18) | 10.76 % |
Dividend Per Share (DPS) | 2.3 sen |
Dividend Yield (DY) | 1.93 % |
Discounted Cash Flow (DCF) 5% Growth | |
Discounted Cash Flow (DCF) 10% Growth | |
Relative Valuation | |
Average Analysts FV based on 4 rating(s) |
Graham Formula | |
Graham Number | |
Net Tangible Asset (NTA) | 0.67 | Consistent QR FV |
Forward PE FV Calculator | |
Latest Profit (adjusted) [M] | 29.29 |
Expected Profit (Next QR) [M] | |
Expected Profit (After QR above) [M] | |
Expected Profit (After QR above) [M] | |
Estimated Fair Value |
Growth/Risk Fair Value Calculator | |
Expected growth (%) | |
Estimated downside / risk (%) | |
Estimated New DCF Fair Value |
Contract/Award Contribution Calculator | |
Contract/Award Value (in Million) | |
Estimated Contribution to Stock Price | |
Estimated New DCF Fair Value |
Profit-Based Calculator | |
Expected Profit (M) | |
for Year | |
Estimated New DCF Fair Value |
Revenue-Based Calculator | |
Expected Revenue (M) | |
for Year | |
Estimated New DCF Fair Value |
Market Pricing | |
Expected Profit (M) | 461.63 |
Expected Revenue (M) | 4254.63 |
Expected Growth (%) | 31.0 |
No transaction in the last 2 months.
Market Cap: 1133 M.
Number of Shares: 952 M.
Adjusted Float: 40.43%.
Stock highly correlated with
HEALTH CARE (97%)
COMFORT (96%)
HARTA (95%)
K1 (95%)
Duopharma Biotech Berhad, formerly known as CCM Duopharma Biotech Berhad. Duopharma core competencies in the pharmaceutical industry include manufacturing, research and development, and commercialization and marketing of over 300 generic drugs, including Omesec and Prelica, as well as Consumer Healthcare (CHC) products such as CHAMPS, FLAVETTES, PROVITON, and Uphamol, which are well-known and accepted by consumers in Malaysia, the region, and around the world. With technological and commercialization agreements with trustworthy and powerful international partners, the Company has also ventured into the biosimilars space.Their headquarters is located in Kuala Lumpur, Malaysia.
Sectors: Consumer Products, Healthcare, Pharmaceuticals, Post MCO, Vaccine
Code: 7148
Website: http://duopharmabiotech.com/
Related Links: Bursa | Annual Report | Announcement
No warrants listed
Updated on 25-Mar-2020
Shareholder | Value (M) |
---|---|
Permodalan Nasional Berhad | 377.85 |
Employees Provident Fund Board | 68.01 |
Amanah Saham Bumiputera | 35.7 |
Billion Victory Sdn Bhd | 20.33 |
Public Islamic Treasures Growth Fund | 8.58 |
Norges Bank | 8.09 |
Manulife Investment Shariah Progressfund | 8.03 |
Kumpulan Wang Persaraan (Diperbadankan) | 6.08 |
Principal Dali Opportunities Fund | 5.5 |
Eastspring Investmentssmall-Cap Fund | 4.99 |
Manulife Investment Progress Fund | 4.99 |
Lembaga Tabung Haji | 4.79 |
Affin Hwang Aiiman Asia (Ex Japan) Growth Fund | 4.0 |
Amanah Saham Malaysia 3 | 3.71 |
Tokio Marine Life Insurance Malaysia Bhd | 3.37 |
Principal Islamic Small Cap Opportunities Fund | 3.25 |
Affin Hwang Growth Fund | 2.9 |
Ooi Keng Tan | 2.62 |
CIMB-Principal Small Cap Fund | 2.55 |
Petroliam Nasional Berhad | 2.51 |
Gibraltar BSN Aggressive Fund | 2.36 |
Affin Hwang Principled Growth Fund | 2.35 |
Medical Fund | 2.2 |
Credit Suisse | 2.2 |
Amtotal Return | 2.1 |
Hong Leong Assurance Berhad | 2.05 |
Areca Equitytrust Fund | 1.96 |